LinkedIn Login, Sign in | LinkedIn
Login to LinkedIn to keep in touch with people you know, share ideas, and build your career.
LinkedIn Login, Sign in | LinkedIn
Login to LinkedIn to keep in touch with people you know, share ideas, and build your career.
LinkedIn Login, Sign in | LinkedIn
Login to LinkedIn to keep in touch with people you know, share ideas, and build your career.
Membranous nephropathy assay: PMND1 - Insights
John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a...
FDA-approved test expands options for Alzheimer's disease - Insights
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for...
PIK3CA assay guides treatment of progressing breast cancer - Insights
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
Chromium and Cobalt - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' synovial fluid testing for patients with symptoms of failed hip arthroplasty. The Food and Drug Administration recommends testing for elevated chromium and cobalt, which can indicate...
Bile acid malabsorption - Insights
Chronic diarrhea and abdominal pain can be caused by many conditions, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), Celiac disease, infectious GI pathogens, and malignancy. When other causes of chronic diarrhea...
Inborn errors of metabolism - Insights
Learn more about how Mayo Clinic Laboratories’ comprehensive menu of biochemical and molecular testing can diagnose inborn errors of metabolism.
Find out how our hereditary cancer panels use next-generation sequencing to evaluate dozens of genes associated with cancer risk.